After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron ...
As it shifts strategic direction to prioritize its recently acquired ENvue feeding tube placement system, NanoVibronix is changing its name to reflect the new focus. | As it shifts strategic direction ...
About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback